regimen schedule has been fixed and the schedule of G-CSF administration and 
PBSC collections made this has to be confirmed with the personnel in the white 
cell room. Day 0 will be fixed on a Monday. 
B. PBSC Collections:. 
(1) PBSC’s are collected by continuous flow centrifugation on days 4 through 6 after 
the first dose of G-CSF. Participants in protocol 691 will undergo an additional 
day of collection on day 3. Aliquots of each days collection will be sent to Dr. 
Schuening for gene insertion procedures as per protocol 691. Day 3 or 4 will be 
scheduled on a Monday to avoid a weekend apheresis. 
C. Infusion of PBSC’s: 
(1) PBSC collections are infused intravenously immediately after collection on post- 
transplant days 0-2. Day 0 for the recipient will be scheduled on a Monday in 
order to avoid apheresis on a weekend. 
9. Evaluation. 
A. Donor: 
(1) All donors will be evaluated as if they were undergoing a marrow harvest. This 
evaluation includes a physical examination, EKG, CBC, CHEM 23, examination 
of serum for Hepatitis B and C, HIV and antibodies against CMV. Donors will 
be examined, weighed and have a CBC before each days’ G-CSF injection. In 
addition, they will have a CBC performed after each pheresis and will have a 
SMA 1260 at the completion of the apheresis procedures. Donors will be 
followed for 2 weeks, if possible, after concluding PBSC donations. After two 
weeks they will have a repeat physical examination, CBC and CHEM 23. 
B. Recipient: 
(1) Studies will be performed as outlined in the primary treatment protocol and in 
protocol 691 for those who participate. 
(2) A complete CBC will be obtained 1 hour after infusion of PBSC’s. 
C. PBSC Collections: 
(1) An aliquot of each collection will be assayed for: total mononuclear cells, 
granulocytes, platelets, red cells, CD34+ positive cells, CFU-GMs and long-term- 
marrow-culture-initiating cells. In selected collections the CD34 + cells will be 
isolated for further sorting by FACS for rhodamine bright and dull cells. The 
quantity of HLA-DR CD2+ and CD3+ cells will be determined on samples from 
all collections from 10 patients by flow cytometry in Dr. Scott Rowley’s 
laboratory. 
10. G-CSF Administration, PBSC Collection and Infusion: Toxicities and Complications. 
A. Drug Formulation: 
(1) G-CSF(Amgen) is obtained from the bacterial fermentation of a strain of E. Coli 
bearing a genetically engineered plasmid containing the human G-CSF gene. G- 
CSF is formulated in a preservative-free solution for injection in vials containing 
300 /xg of protein per ml in 1 or 1.6 ml vials respectively. The vials are stored at 
2-8°C. For subcutaneous injection 2-3 of the 300 /xg or 480 /xg vials will be - 
Recombinant DNA Research, Volume 16 
[367] 
